HLA-associated drug hypersensitivity and the prediction of adverse drug reactions by Negrini, S. & Becquemont, L.
Review
For reprint orders, please contact: reprints@futuremedicine.com
HLA-associated drug hypersensitivity and the
prediction of adverse drug reactions
Simone Negrini*,1,2 & Laurent Becquemont3,4
1Department of Internal Medicine, Clinical Immunology Unit, University of Genoa, Genoa, Italy
2Center of Excellence for Biomedical Research, University of Genoa, Genoa, Italy
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Adverse drug reactions are an important cause of morbidity and mortality and constitute the leading
reason of drug withdrawal from the market. Besides classical reactions that are related to pharmacologic
activity of the drug, some reactions are unpredictable, not dose dependent, and seem to occur in geneti-
cally predisposed individuals. The majority of this reaction is immunologically driven and they are referred
to as hypersensitivity reactions. A growing number of studies provided evidences that specific HLA alleles
increase the risk of developing hypersensitivity drug reactions. In this context, drug hypersensitivities that
have more robust pharmacogenetic data include abacavir hypersensitivity syndrome and severe cutaneous
adverse reactions induced by allopurinol and carbamazepine.
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Personalized medicine aims to individualize treatment strategies in order to improve the efficacy of therapy and
reduce adverse drug reactions (ADRs). Several genetic and nongenetic factors can affect drug responses among
individuals, in this scenery, pharmacogenomics is the discipline that studies individual’s genetic characteristics that
influence drug efficacy and safety. Interestingly, a recent study reported that about 30% of ADRs are related to
drugs with a clinical annotation in the Pharmacogenomics Knowledge Base, suggesting that some of these reactions
could have been avoided by pharmacogenetic testing [1]. ADRs are defined by the WHO as an unintended and
deleterious response to a pharmaceutical product occurring at a dose normally used in man [2]. In a large historical
meta-analysis, Lazarou et al. reported an overall incidence of serious ADRs of 6.7% and fatal ADRs of 0.32%
in hospitalized patients, and estimated that ADRs are responsible for more than 100,000 deaths annually thus
representing the fourth to sixth leading cause of death in the USA [3]. In Europe, it is estimated that 5% of all
hospitalizations and 197,000 fatal cases per year are related to ADRs [4]. Along with the mortality and morbidity
impact, the economic cost to society of ADRs amount to $177 billion in the USA and €79 billion in Europe [4,5].
Moreover, ADRs are the leading cause of drug withdrawal from the market thus representing a huge cost burden
for pharmaceutical companies [6].
Historically, ADRs are classified into two main categories: Type A (‘Augmented’) and Type B (‘Bizarre’) reac-
tions [7]. Type A reactions are predictable, dose dependent, occur in all individuals and could be explained by the
pharmacologic activity of the drug (on-target). Type B (off-target) reactions, responsible for at least 15% of all
ADRs, are unpredictable, dose independent and, being related to host genetics, are also named as ‘idiosyncratic
reactions’ [8]. The majority of type B reactions are driven by the immune system, and they are therefore defined
as hypersensitivity drug reactions (HDRs). Based on timing of symptoms onset, hypersensitivity reactions may be
further classified as immediate or delayed, suggesting also the immunologic mechanism underlying the reaction [9].
‘Immediate reactions’ cause symptoms appearance immediately after drug uptake (mostly <1 h), are IgE mediated
and clinical manifestations include angioedema, urticaria, bronchospasm and anaphylaxis. ‘Delayed hypersensitivity
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reactions’ typically occur days, or even weeks, after drug exposure and are mediated by T lymphocytes. Delayed-
type HDRs include a heterogeneous spectrum of systemic syndromes, also called drug rash with eosinophilia
and systemic symptoms (DRESS syndrome) and organ-specific manifestations, most notably cutaneous reactions,
and liver injury [8,9]. These HDRs have to be distinguished from autoimmune syndromes induced by the newly
released checkpoint inhibitors (e.g., CTLA-4, PD1 and PDL1 antagonist) that are type A ADRs, related to their
immunostimulant pharmacological properties and therefore out of the scope of this review.
Immunopathogenic mechanisms involved in HDRs
MHC molecules play a pivotal role in T-cell activation since this process obligatorily requires that the T-cell receptor
(TCR) engages with the complementary antigenic peptide bound to MHC molecules. There are two main families
of HLA molecules: MHC class I molecules are expressed by virtually all nucleated cells and present peptides derived
from intracellularly expressed proteins to cytotoxic CD8+ T cells. MHC class II proteins are typically expressed
by professional antigen-presenting cells, such as dendritic cells, and serve to present internalized exogenous protein
to CD4+ T-helper lymphocytes. The HLA system is the gene complex, located on the short arm of chromosome
6, that encodes MHC proteins in humans. HLA class I molecules are encoded by three loci known as HLA-A,
HLA-B and HLA-C, and HLA class II molecules are encoded by HLA-DR, HLA-DQ and HLA-DP genes [10].
The HLA system is the most polymorphic genetic region in the human genome. This variability in HLA molecules
results from the need to present a huge variety of peptides. HLA polymorphisms principally influence the shape
and electrochemistry of the peptide-binding groove that consequently determine the repertoire of peptides that
can bind to a specific HLA molecule. The prevalence of specific HLA alleles differs significantly among different
populations and ethnic groups, this phenomenon is linked to the selective pressure exerted by specific factors
prevalent in different geographic areas, in particular infectious agents [10,11].
Taking into account the role played by HLA in the adaptive immune response, it is not surprising that certain
HLA alleles may predispose to (or protect from) disorders in which the immune system is strongly implicated, such
as autoimmunity, cancers or infectious diseases [12,13]. Similarly, certain HLA alleles have been associated with an
increased risk of delayed HDRs. Since HLA expression is co-dominant, the predisposition to drug hypersensitivity
‘simply’ depends on the presence of the relevant allele associated to a specific drug. Heterozygote and homozygous
individuals have an increased risk of drug-induced hypersensitivity, on the other hand, the absence of the allele
indicates that the patient has a very low risk of HDR associated to a specific drug. Consequently, HLA genotyping
results are reported as either ‘positive’ or ‘negative’, with no intermediate phenotype [10].
As mentioned, T cells recognize the cognate antigen only if the latter is bound stably in the peptide-binding cleft
of the MHC molecule. For this to happen, peptide must have specific dimensional characteristics. However, the
large majority of drugs are smaller (molecular weights <1 kDa) than the peptide ligands of HLA class I (8–12 amino
acids) and class II (9–25 amino acids) molecules, having a size comparable to 1–3 amino acids [14]. Therefore three
main immunopathogenic models have been proposed in order to explain how drugs can activate T cells and provoke
an immune response. These theories are: the ‘hapten/prohapten model’, the ‘pharmacological interaction (p-i) with
immune receptors concept’ and the ‘altered peptide repertoire hypothesis’ (Figure 1). The ‘hapten/prohapten model’
proposes that a chemically reactive drug, acting as hapten, binds covalently a self-protein (carrier) creating a fully
antigenic complex. This neo-antigen is processed by the antigen-presenting cell, loaded onto the HLA molecule
and then presented to the cognate T cell. Similarly, the prohapten is a chemically inert drug that becomes reactive
upon metabolism [15]. The ‘pi-concept hypothesis’ proposes that a chemically nonreactive drug, which is unable to
haptenate carrier molecules, can elicit an immune response by interacting directly with the immune receptors (TCR
and/or the HLA molecule) independently from the peptide. This interaction needs neither metabolism nor antigen
processing [8]. The initial stimulation of the immune receptors is further enhanced by TCR–HLA interaction and
probably involves hyper-reactive T cells with a low activation threshold [16–18]. According to the ‘altered peptide
repertoire hypothesis’, a drug binds the antigen-binding cleft of HLA and, modifying its conformation, alters
the repertoire of self-peptides that are bound and presented. Since during thymic maturation, T cells are selected
to be tolerant to a specific pool of self-peptides, the presentation of these neo-self-peptides may induce T-cell
activation. Recent data suggest that the altered repertoire mechanism is implicated in HDRs related to abacavir
and carbamazepine [19]. It is noteworthy that the above-mentioned immunopathogenic theories are nonmutually
exclusive and probably a specific mechanism may be prevalent for a given drug but not for another. To date, the
best characterized HLA–HDRs associations include abacavir, allopurinol and carbamazepine.
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Figure 1. Schematic representation of the immunopathogenic models of T-cell activation by drugs.The repertoire of
peptides that can bind to a given HLA molecule is dictated by the shape and electrochemistry of the peptide-binding
cleft which in turn depends on its amino acid composition. Hapten/prohapten model, the drug (or its metabolite)
binds to self-proteins (carriers) creating a neo-antigen. The latter is processed by the antigen-presenting cell, loaded
onto the HLA molecule and then presented to T cells. According to the ’p-i concept’, the drug binds directly to MHC
molecules and/or TCR, activating T cells. The ‘altered peptide hypothesis’ suggests that the drug can bind to the
HLA-binding cleft and, altering the specificity of peptide binding, change the repertoire of self-peptides presented.
This results in the presentation of neo-self-peptides capable to trigger an immune response.
APC: Antigen-presenting cell; TCR: T-cell receptor.
Abacavir
Abacavir is a reverse-transcriptase inhibitor used in combination therapies for the treatment of HIV infection.
Abacavir is generally well tolerated, but 5–7% of exposed patients develop a hypersensitivity syndrome [20]. This
syndrome worsens if the treatment is not withdrawn and rechallenge after drug discontinuation can be potentially
fatal. The clinical diagnostic criteria for abacavir-induced HDR require at least two symptoms of fever, rash, nausea,
vomiting, headache, lethargy, myalgia, arthralgia or gastrointestinal symptoms, occurring within the first 6 weeks
of therapy and resolving within 72 h of withdrawal of the drug. Less frequent manifestations include respiratory
symptoms, paresthesia, edema, renal or hepatic failure [21]. Even if abacavir hypersensitivity was described in early
phases of drug development, only in 2002, two independent groups reported a strong association between the
HLA-B*57:01 allele and increased risk of developing abacavir-related HDR [22,23]. Thereafter, this association
was further reported by other researchers [24–27], but it was definitively confirmed in 2008 with the ‘Prospective
Randomized Evaluation of DNA Screening in a Clinical Trial 1’, the largest randomized clinical trial conducted so
far in pharmacogenetics. In this study, 1956 patients from 19 countries were prospectively randomized into two
arms: an experimental arm in which HLA-B*5701 carriers did not receive abacavir and a control arm, corresponding
to the ‘standard of care’ at the time of the study, in which patients received the treatment without genetic testing.
The incidence of immunologically confirmed (via patch testing) abacavir hypersensitivity reactions was 0% in
the HLA-B*57:01 negative group as compared with 2.7% in the control (no screening) group indicating that
pretreatment HLA-B*5701 genotyping was capable to effectively prevent hypersensitivity reactions to abacavir [28].
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Despite these remarkable results, the generalizability of the Prospective Randomized Evaluation of DNA Screen-
ing in a Clinical Trial 1 results to all ethnicities was questioned because of the high prevalence of Caucasian in
the enrolled population – that is 84% of the patients. The SHAPE trial, a case-control study enrolling similar
percentages of black and white subjects, demonstrated a 100% negative predictive value (NPV) of HLA-B*57:01
testing for abacavir hypersensitivity for both races, thus confirming the value of the screening across different
ethnicities [29]. A recent systematic review and meta-analysis of the literature further confirmed that HLA-B*57:01
carrier status is significantly associated with abacavir-induced hypersensitivity reactions in Whites, Blacks and
Hispanics; in this paper the authors comment that the initially perceived lack of predictive value in non-Caucasians
was probably due to the low carriage rate of HLA-B*57:01, the high rates of false-positive clinical diagnosis of HDR
in nonwhite patients and the low number of nonwhite subjects enrolled in early studies [30]. The positive predictive
value (PPV) of HLA-B*57:01 genetic screening is estimated to be around 50%, consequently, approximately half
of all HLA-B*57:01-positive patients actually will never develop the HDR if treated with abacavir indicating that
HLA-B*57:01 is necessary but not sufficient to develop abacavir hypersensitivity. On the other hand, the NPV is
100%, this means that HLA-B*57:01-negative individuals will not develop hypersensitivity thus making this test
very useful for predicting the risk of abacavir-related HDR [28].
This large body of scientific evidence, prompted regulatory agencies, such as US FDA and EMA, and different
clinical guidelines to recommend the genotyping for HLA-B*57:01 before abacavir administration [31,32]. The
‘real-life’ clinical impact of the systematic genotyping in patients candidate for abacavir-based treatments has been
acknowledged through follow-up studies which have demonstrated an important decrease in the number of abacavir
hypersensitivity cases thus confirming its value and cost–effectiveness [33–36]. At this time, HLA-B*57:01 screening
is the most commonly prescribed pharmacogenetic test in clinical practice.
It is worth mentioning that abacavir-specific T-cell responses can be activated only by the HLA-B*57:01 allele,
whereas closely related HLA allotypes such as HLA-B*57:02 or -B*57:03 do not. [37]. Conversely, it has been
recently reported that HLA-B*57:02 and -B*57:03 alleles, but not the HLA-B*57:01, confer susceptibility to
develop liver toxicity in patients receiving antituberculosis and antiretroviral drugs co-treatment [38]. This notion
clearly underlines that HLA genotyping should have at least 4-digit resolution (high resolution), because low
resolution (2-digit) typing do not allow to discriminate among closely related alleles which may have completely
different impact over a specific adverse reaction. Interestingly, the HLA-B*57:01-related susceptibility to develop
HDRs is not limited to abacavir hypersensitivity, in fact this allotype has been also associated with liver injury
induced by pazopanib and flucloxacillin, a tyrosine kinase inhibitor and a β-lactam antibiotic, respectively [39,40].
These data clearly indicate that the same HLA allele may induce clinically different hypersensitivity reactions
triggered by chemically unrelated drugs.
Allopurinol
Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN, also known as Lyell’s syndrome) are
severe bullous mucocutaneous reactions characterized by an extensive skin detachment. The extent of the skin
involvement defines the clinical subtype of the disease (<10% in SJS, 10–30% in SJS/TEN overlap syndrome and
>30% in TEN) and influence the different prognoses of each of these conditions [41]. SJS/TEN is rare (estimated
incidence of 2–6 cases/million per year) but both conditions are associated with significant long-term morbidity,
including scarring and blindness, and mortality (rates ranging from 5% for SJS to 50% for TEN) [41]. The precise
pathophysiology of SJS/TEN is not entirely elucidated, however it seems to depend on the killing of epithelial cells
mediated by autoreactive CD8+ cytotoxic T lymphocytes through the release of cytolytic mediators (soluble-FasL,
granzyme B, perforin, granulysin) and pro-inflammatory cytokines [42–44]. The large majority of cases of SJS/TEN
are caused by drugs and several medications are considered at high risk of inducing SJS/TEN [42].
Allopurinol is a xanthine oxidase inhibitor commonly prescribed for the treatment of hyperuricemia-associated
disorders, such as chronic gout, uric acid nephrolithiasis and tumor lysis syndrome. Allopurinol is generally
considered safe, nevertheless it can induce hypersensitivity reactions, with clinical manifestations ranging from
mild cutaneous erythema to most serious conditions which include DRESS and SJS/TEN, the latter occurring in
approximately 0.1–0.4% of the exposed patients [45]. Allopurinol is the most frequent cause of SJS/TEN in Europe,
largely surpassing carbamazepine and phenytoin, while in southeast Asia, it is the second most common SJS/TEN-
causative drug following carbamazepine [46,47]. In 2005, a Taiwanese research group performed a candidate gene
analysis comparing 51 patients with allopurinol-induced HDRs with 135 allopurinol-tolerant subjects and 93
healthy subjects from the general population. In this way, they discovered that HLA-B*58:01 allele was present
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in all patients with allopurinol-induced severe cutaneous ADRs compared with only 15% of allopurinol-tolerant
patients and 20% of healthy controls [48]. As previously discussed, the presence of HLA-B*5801 in the tolerant
group suggests that other contributing factors should intervene in the pathogenesis of hypersensitivity. In this
study all the enrolled subjects were of Han Chinese ancestry, but similar results have been further confirmed
in other ethnicities: strong association was found in Thais, Japanese and Koreans while a significant but weaker
association was reported in Europeans [43,49–53]. This difference might be due to the different allelic frequency of
HLA-B*58:01 across different populations, which is higher in Asian populations (e.g., 20% in Han Chinese) as
compared with Europeans (approximately 1–2%) and/or additional contributing factors not yet identified. Anyway,
a recent meta-analysis confirmed the strong and significant association between HLA-B*58:01 carrier status and
allopurinol-induced SJS/TEN (OR: 96.60 and OR: 79.28 in studies with matched-control or population-control,
respectively) in both Asian and non-Asian populations [54].
From an immunopathogenic point of view, allopurinol-related HDR is mediated by T cells reacting with
allopurinol and, more importantly, its metabolite, oxypurinol. Surprisingly, the activation of T cells reactive to
allopurinol and oxypurinol is dose dependent albeit this observation appears in conflict with the dogma that HDRs
are unpredictable and dose independent. In fact, a higher starting dose and renal insufficiency (negatively influencing
the clearance of the drug) have been indicated as additional risks factor for allopurinol-related HDRs [44,55].
In consideration of the strong association between HLA-B*58:01 and hypersensitivity reactions to allopurinol
across different populations, a genetic screening will be probably adopted in future, nevertheless prospective studies
are still necessary to clearly confirm the value of this test in routine clinical practice. To date, FDA and EMA
have not implemented allopurinol-labeling information for HLA-B*58:01 genotyping [31,32]. The Pharmaceuticals
and Medical Devices Agency (Japan) package insert only mentions that HLA-B*58:01 allele is present at a
high frequency in patients with SJS/TEN who came from Han Chinese, Japanese or European populations,
but pretreatment pharmacogenetic screening is not required or recommended. The Clinical Pharmacogenetics
Implementation Consortium guidelines recommend that allopurinol should not be prescribed to patients who are
positive for the HLA-B*5801 allele but underscore that a negative genotyping does not exclude the possibility
of severe HDRs, especially in European populations [45]. The 2012 revised American College of Rheumatology
guidelines for the management of gout also recommend HLA-B*58:01 screening prior to initiating allopurinol,
especially in those populations with high frequencies of the allele (e.g., Koreans with stage ≥3 chronic kidney
disease and all those of Han Chinese and Thai descent) [56].
Carbamazepine
Carbamazepine is an aromatic anticonvulsant used in the treatment of epilepsy, neuropathic pain and bipolar
disorder. Carbamazepine has been associated with maculopapular eruption (MPE), DRESS syndrome (also known
as drug-induced hypersensitivity syndrome [DIHS]) and less frequently SJS/TEN [10]. These reactions are relatively
rare in Western populations (1–6 cases in every 10,000 exposed patients) but occur ten-times more frequently in
certain Asian populations, such as Han Chinese [57].
In 2004, Chung et al. described a strong association between carbamazepine-related SJS/TEN and the HLA-
B*15:02 allele in Han Chinese patients from Taiwan. They observed that the HLA-B*15:02 allele was present in
all patients with carbamazepine-related SJS/TEN as compared with only 3% of drug-tolerant subjects and 8.6%
of the general population [58]. Several other studies have confirmed this association in other Asian ethnicities such
as Han Chinese from China, Thai, Korean, Malay, Vietnamese and Indian populations [47,59–67]. Three recent
meta-analyses that reviewed data obtained from different Asian populations found odds ratios of approximately 80
for carbamazepine-induced SJS/TEN in HLA-B*15:02 carriers [68–70]. In 2011, the same investigators from Taiwan
designed a large prospective study to evaluate the benefits of HLA-B*15:02 pretreatment screening. In this trial,
4120 HLA-B*1502-negative patients were treated with carbamazepine while 215 HLA-B*1502-positive subjects
were treated with an alternative drug. The authors observed that SJS/TEN did not develop in any of the treated
patients. If compared with the estimated historical incidence of carbamazepine-induced SJS-TEN (0.23%), the
HLA-B*15:02 pretreatment screening effectively prevented ten cases of HDR [71]. These impressive results lay the
foundations for the use of HLA B*15:02 screening before carbamazepine therapy in Asian patients. The observation
that not all patients carrying the HLA-B*15:02 allele develop carbamazepine-associated HDR prompted Ko and
colleagues to analyze the TCR repertoire of patients with carbamazepine-induced hypersensitivity [72]. Their study
showed that the TCR clonotype, VB-11-ISGSY, was present in 84% of HLA-B*15:02-positive patients with
carbamazepine-associated SJS/TEN but it was absent in all tolerant subjects, including two individuals who
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were HLA-B*15:02 carriers. These data imply that HLA-B*15:02 and the VB-11-ISGSY TCR clonotype may
synergically contribute to the development of HDR and T-cell activation is not only restricted to specific HLA
allotype but also to particular TCR clonotypes [72]. In Caucasian or Japanese populations, HLA-B*15:02 has
not been found to be a risk factor in carbamazepine-induced HDR, most likely because this allele has a very low
frequency in these ethnic groups (<1%). In these populations, recent data report that the presence of HLA-A*31:01
predisposes to different hypersensitivity phenotypes, including SJS/TEN, MPE and DRESS [68,73–76]. It is worth
noting that in Han Chinese, HLA-A*31:01 allele has been associated with an increased risk of carbamazepine-
induced MPE or DRESS, while SJS/TEN are related to HLA-B*15:02 expression [60,68,77]. These data indicate that
genetic predisposition to carbamazepine-triggered HDRs, at least in certain populations, are phenotype-specific.
Interestingly, although HLA-B*15:02 and HLA-A*31:01 differ greatly from each other in amino-acid sequence,
they share two of the three amino acid residues involved in the interaction with carbamazepine, this observation may
explain how two different HLA allotype may effectively interact with the same antigen [78]. Besides HLA-B*15:02
and HLA-A*31:01, other HLA alleles have been reported to increase the risk of carbamazepine-related reactions
in various populations (Table 1), however these data are limited and need further verification. Nevertheless, it is
interesting to observe that some of these alleles (e.g., HLA-B*15:11, HLA-B*15:08 and HLA-B*15:21) belong to
the same HLA-B75 serotype as well as HLA-B*15:02, suggesting that the members of HLAB75 family may share
the ability to bind carbamazepine and activate drug-specific immune response [79].
FDA and EMA have included warnings in the drug label and summary of product characteristic, respectively,
recommending HLA-B*15:02 genetic testing prior to a carbamazepine-based treatment in patients of Asian ances-
try [31,32]. Regarding HLA-A*31:01, FDA added a warning to the prescribing information, stating that the risks
and benefits of using carbamazepine should be balanced in positive individuals, but pharmacogenetic screening is
not currently mandated [32]. Similarly, specific warnings have been included in a number of drug labels worldwide
but the association of HLA-A*31:01-HDR is mentioned for information only. To date, only the Canadian Pharma-
cogenomics Network for Drug Safety and the Canadian Department for National Public Health (Health Canada –
Santé Canada) recommend pharmacogenetic testing for HLA-A*31:01 prior to carbamazepine in patients of all
ancestries [80]. Nevertheless, considering the relative low number of patients needed to be screened to prevent a case
of carbamazepine hypersensitivity (47 Caucasians and 67 Japanese patients), it is very likely that HLA-A*31:01
genetic screening will be implemented in the future [81].
Different studies report that HLA-B*15:02 could be also related with SJS/TEN induced by other anticonvulsants,
such as oxcarbazepine, phenytoin and lamotrigine [60,68,82]. These findings suggest that HLA-B*15:02 carriers may
show cross-reactivity to aromatic antiepileptic drugs, other than carbamazepine, and consequently special attention
should be given when considering antiepileptic treatment for HLA-B*1502-positive patients [83]. At present,
FDA recommends to avoid phenytoin as an alternative for carbamazepine in HLA-B*1502 carriers, and suggests
testing for HLA-B*1502 allele prior to oxcarbazepine in patients with ancestry in genetically at-risk populations
(e.g., Han Chinese and Thai, Philippines and Malaysian populations). To date, FDA does not provide specific
recommendations concerning lamotrigine [32].
Conclusion & future perspective
Abacavir, carbamazepine and allopurinol are key examples of pharmacogenetics implementation in routine medical
practice demonstrating to be both clinically useful and cost effective [84], but a huge number of other HLA-
related HDRs have been described to date (Table 1). A complete listing is available on the Pharmacogenomics
Knowledge Base website [85,86]. Successful clinical implementation of a specific pharmacogenetic biomarker can
be schematically resumed in four phases: discovery, clinical validity and utility, implementation and positive effect
on public health [87]. However, the large majority of the HLA–drug–HDR associations described so far are still
relegated in a preliminary phase (discovery) and thus need further investigation to confirm their translational
potential.
Several concerns should be taken into consideration before HLA–HDR associations could be successfully
translated in screening procedures. In this context, it is interesting to observe that 10% of drug labels contain
information on genetic factors influencing drug safety, but only a limited number of genetic tests are presently
employed in clinical routine [88]. Factors influencing the translatability of a given pharmacogenetic testing into
clinical practice have been extensively analyzed by different authors [87,89–90]. Concerning HLA-related HDR
pharmacogenetic testing, the main critical issues are: drug toxicity should be severe and frequent, NPV (and ideally
also the PPV) should reach 100%, the incriminated HLA allele should be sufficiently frequent inside the target
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Table 1. Most significant pharmacogenomics associations between classical HLA allelic variants and drug hypersensitivity






Population(s) Risk of ADR Clinical implementation
Abacavir 1A HLA-B*57:01 DRESS Mixed
population




DPWG: alternative drug for positive patients,
HIV Treatment Guidelines and National
Authorities: testing required or recommended
Acetazolamide 4 HLA-B*59:01 SJS/TEN Asian (Korean) Increased N/A
Acetaminophen 3 HLA-DQB1*02:02 SJS/TEN Caucasian
(Italian)
Increased N/A
Allopurinol 1A HLA-B*58:01 SJS/TEN Mixed
population
Increased European national competent
authorities: warning (no genotyping
recommendations),









2B HLA-C*03:02 SJS/TEN Mixed
population
Increased
3 HLA-A*02:01 SJS/TEN Asian Decreased
3 HLA-B*48:01 Drug
hypersensitivity





















3 HLA-DR9; HLA-DR14 MPE Asian Increased




















White TT genotypes have
a decreased risk



















Aspirin 2B HLA-DPB1*03:01; Asthma Mixed
population
Increased N/A
†PharmGKB levels of evidence for clinical annotations. Levels of evidence vary from 1 (robust data, most important associations) to 4 (less-consistent associations). PharmGKB curators
periodically review the level of evidence of clinical annotations, therefore, the level of evidence may change over time as a result of additional studies performed.
ACR: American College of Rheumatology; ADR: Adverse drug reaction; CPIC: Clinical Pharmacogenetics Implementation Consortium; CPNDS: Canadian Pharmacogenomics Network
for Drug Safety; DILI: Drug-induced liver injury; DPWG: Dutch Pharmacogenetics Working Group; DRESS: Drug reaction with eosinophilia and systemic symptom; HCSC: Health Canada
(Santé Canada); MPE: Maculopapular eruption, N/A: Not applicable; PharmGKB: Pharmacogenomics Knowledge Base; PMDA: Pharmaceuticals and Medical Devices Agency – Japan;
SJS: Stevens–Johnson syndrome; TEN: Toxic epidermal necrolysis.
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Table 1. Most significant pharmacogenomics associations between classical HLA allelic variants and drug hypersensitivity






Population(s) Risk of ADR Clinical implementation





Asthma Asian AA genotypes have
a decreased risk







Pancreatitis European Increased N/A
Carbamazepine 1A HLA-B*15:02 SJS/TEN Mainly Asian† Increased HLA-B*15:02
FDA: boxed warning, test required (patients
with Asian ancestry), European national
competent authorities: warning, test
recommended (patients with Asian ancestry),
PMDA: label information,
HCSC: test recommended,
CPNDS: drug contraindicated for positive
patients
HLA-A*31:01
FDA: warning (no genotyping
recommendations),
European national competent
authorities: warning (no genotyping
recommendations),
PMDA: label information,
HCSC: test recommended, CPNDS: drug
contraindicated for positive patients





















3 HLA-B*15:18 SJS/TEN Asian (Japanese) Increased
3 HLA-B*58:01 MEP Asian (Han
Chinese)
Decreased





3 HLA-B*59:01 SJS/TEN Asian (Japanese) Increased
3 HLA-B*13:01 Drug
hypersensitivity
Caucasian, Asian Increased (not in all
studies)






3 HLA-DRB1*03:01 MEP Asian (Han
Chinese)
Increased
†PharmGKB levels of evidence for clinical annotations. Levels of evidence vary from 1 (robust data, most important associations) to 4 (less-consistent associations). PharmGKB curators
periodically review the level of evidence of clinical annotations, therefore, the level of evidence may change over time as a result of additional studies performed.
ACR: American College of Rheumatology; ADR: Adverse drug reaction; CPIC: Clinical Pharmacogenetics Implementation Consortium; CPNDS: Canadian Pharmacogenomics Network
for Drug Safety; DILI: Drug-induced liver injury; DPWG: Dutch Pharmacogenetics Working Group; DRESS: Drug reaction with eosinophilia and systemic symptom; HCSC: Health Canada
(Santé Canada); MPE: Maculopapular eruption, N/A: Not applicable; PharmGKB: Pharmacogenomics Knowledge Base; PMDA: Pharmaceuticals and Medical Devices Agency – Japan;
SJS: Stevens–Johnson syndrome; TEN: Toxic epidermal necrolysis.
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Table 1. Most significant pharmacogenomics associations between classical HLA allelic variants and drug hypersensitivity






Population(s) Risk of ADR Clinical implementation
3 HLA-A*24:02 DRESS, SJS/TEN Mixed
population
Increased
3 HLA-A*11:01 SJS/TEN Mixed
population
Increased
3 HLA-C*08:01 SJS/TEN White Increased











Clozapine 3 HLA-DRB3*02:02 Agranulocytosis Caucasian Increased N/A




































while AG and GG
genotypes have an
increased risk





Lamotrigine 3 HLA-B *58:01 SJS/TEN Mixed
population
Increased N/A
3 HLA-B *15:02 SJS/TEN Asian Increased (only
found in
meta-analyses)
3 HLA-B*38:01 SJS/TEN White Increased




Increased HLA-DQA1*02:01 or HLA-DRB1*07:01 alleles
carrier FDA, EMA, PMDA and HCSC: warning
(no genotyping recommendations)














Increased Withdrawn from the market or not approved
following cases of hepatotoxicity in 2007




2B HLA-C *01:02 SJS/TEN Asian (Korean,
Chinese)
Increased
†PharmGKB levels of evidence for clinical annotations. Levels of evidence vary from 1 (robust data, most important associations) to 4 (less-consistent associations). PharmGKB curators
periodically review the level of evidence of clinical annotations, therefore, the level of evidence may change over time as a result of additional studies performed.
ACR: American College of Rheumatology; ADR: Adverse drug reaction; CPIC: Clinical Pharmacogenetics Implementation Consortium; CPNDS: Canadian Pharmacogenomics Network
for Drug Safety; DILI: Drug-induced liver injury; DPWG: Dutch Pharmacogenetics Working Group; DRESS: Drug reaction with eosinophilia and systemic symptom; HCSC: Health Canada
(Santé Canada); MPE: Maculopapular eruption, N/A: Not applicable; PharmGKB: Pharmacogenomics Knowledge Base; PMDA: Pharmaceuticals and Medical Devices Agency – Japan;
SJS: Stevens–Johnson syndrome; TEN: Toxic epidermal necrolysis.
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Table 1. Most significant pharmacogenomics associations between classical HLA allelic variants and drug hypersensitivity






Population(s) Risk of ADR Clinical implementation
Methotrexate 3 HLA-C*06:02 Better response Tamil (psoriasis) N/A N/A
Minocycline 3 HLA-B*35:05 Drug-induced
liver injury
White Increased N/A
















to be dependent on
CD4+ T-cell count)







3 HLA-B*35:05 Skin rash Asian (Thai) Increased








3 HLA-DRB1 *11:01 Anaphylactic
reactions
White Increased N/A
Oxcarbazepine 3 HLA-B *13:02 MEP Asian (Chinese) Increased HLA-B*15:02
FDA: warning, test recommended in genetically
at-risk populations
3 HLA-B *15:02 MEP, SJS/TEN Asian Increased

















Pazopanib N/A HLA-B*57:01 DILI Mixed
population








N/A DPWG: information about lower response in
HLA-B*44-negative patients (no genotyping
recommendations)















Thai (hepatitis B) N/A N/A
†PharmGKB levels of evidence for clinical annotations. Levels of evidence vary from 1 (robust data, most important associations) to 4 (less-consistent associations). PharmGKB curators
periodically review the level of evidence of clinical annotations, therefore, the level of evidence may change over time as a result of additional studies performed.
ACR: American College of Rheumatology; ADR: Adverse drug reaction; CPIC: Clinical Pharmacogenetics Implementation Consortium; CPNDS: Canadian Pharmacogenomics Network
for Drug Safety; DILI: Drug-induced liver injury; DPWG: Dutch Pharmacogenetics Working Group; DRESS: Drug reaction with eosinophilia and systemic symptom; HCSC: Health Canada
(Santé Canada); MPE: Maculopapular eruption, N/A: Not applicable; PharmGKB: Pharmacogenomics Knowledge Base; PMDA: Pharmaceuticals and Medical Devices Agency – Japan;
SJS: Stevens–Johnson syndrome; TEN: Toxic epidermal necrolysis.
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Table 1. Most significant pharmacogenomics associations between classical HLA allelic variants and drug hypersensitivity






Population(s) Risk of ADR Clinical implementation
Phenobarbital 3 HLA-B *51:01 SJS/TEN Asian Increased N/A
Phenytoin 1A HLA-B *15:02 SJS/TEN Asian Increased B *15:02
FDA: warning (avoid drug in positive patients),
CPIC: drug contraindicated for positive patients,
HCSC: test recommended
3 HLA-B *13:01 SJS/TEN Asian Increased (not
increased in one
study)
3 HLA-C*08:01 MPE, SJS/TEN Mixed
population










3 HLA-DRB1 variants Statin-related
myopathy






Sulfasalazine 3 HLA-B *39:01; HLA-B
*13:01
DRESS Asian Increased N/A





2A HLA-B *38:02:01 Agranulocytosis Mixed
population
Increased N/A






Trichloroethylene 3 HLA-B *13:01 Hypersensitivity
dermatitis
Asian (Chinese) Increased N/A






White (psoriasis) N/A N/A







European Increased Withdrawn from the market in 2006 following
reports of hepatotoxicity
Zonisamide 3 HLA-A *02:07:01 SJS/TEN Asian (Japanese) Increased N/A
†PharmGKB levels of evidence for clinical annotations. Levels of evidence vary from 1 (robust data, most important associations) to 4 (less-consistent associations). PharmGKB curators
periodically review the level of evidence of clinical annotations, therefore, the level of evidence may change over time as a result of additional studies performed.
ACR: American College of Rheumatology; ADR: Adverse drug reaction; CPIC: Clinical Pharmacogenetics Implementation Consortium; CPNDS: Canadian Pharmacogenomics Network
for Drug Safety; DILI: Drug-induced liver injury; DPWG: Dutch Pharmacogenetics Working Group; DRESS: Drug reaction with eosinophilia and systemic symptom; HCSC: Health Canada
(Santé Canada); MPE: Maculopapular eruption, N/A: Not applicable; PharmGKB: Pharmacogenomics Knowledge Base; PMDA: Pharmaceuticals and Medical Devices Agency – Japan;
SJS: Stevens–Johnson syndrome; TEN: Toxic epidermal necrolysis.
population and the number of patients needed to test in order to prevent a case is low. Furthermore, the drug for
which genetic test is postulated, should have good efficacy, cost–effectiveness and tolerability, in the absence of
alternative therapies with comparable positive features [57].
From the examples of HLA–HDR–drug associations discussed above, it emerges clearly that certain individuals
positive for a susceptibility HLA allele do not develop hypersensitivity if exposed to the culprit drug. This
notion implies two major considerations, largely generalizable to other HLA-associated HDRs. First, a particular
HLA allotype is necessary (high NPV) but not sufficient (low PPV) for disease to occur, and additional genetic
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Table 2. Additional risk factors, other than HLA, involved in drug hypersensitivity (not exhaustive listing).
Risk factors Examples and comments
Concomitant virus reactivation or infections HIV and herpes viruses
Factors that influence drug levels (environmental and genetic) Dosage and chronic renal insufficiency in allopurinol-induced HDRs, synergistic
effect of HLA-A*33:03 and gain-of-function variants in CYP2B6 on
ticlopidine-induced DILI, HLA-DRw4 and slow acetylator phenotype in
hydralazine-induced Systemic Lupus Erythematosus
Female sex Immune-related diseases are more common in women (e.g., autoimmune disorders)
but influence of sex on HDRs is not clearly defined
Genes involved in cytokine production TNF-alpha promoter polymorphism and HLA DPB1*0301 in aspirin-induced asthma,
or HLA-DR3 and -DQ2 in carbamazepine-related HDR
Immune status of patients CD4 T-cell counts and nevirapine HDR, CD8+ T-cell counts in abacavir HDR
Intrinsic immunogenicity of the drug Structurally related aromatic anticonvulsants may induce HDRs (e.g., HLA-B*15:02
and HDRs related to various aromatic antiepileptic drugs)
Race, ethnicity Frequency of a given HLA allotype differs across populations, but other, still
unknown, factors may be involved
T-cell receptor repertoires HLA-B*15:02 and VB-11-ISGSY TCR clonotype may synergically contribute to
carbamazepine-related HDR
and/or environmental causal factors should be at play (Table 2) [91,92]. Unfortunately, the characterization of these
contributing factors is still largely incomplete, and there is a need of further research on this topic. Accordingly,
HLA typing should be accompanied by the analysis of additional individual’s characteristics and risk factors
in order to better delineate patients with an increased risk of a particular hypersensitivity, thus improving the
efficacy/predictivity of the screening. Second, it is clear that, although on the one hand HLA screening reduce the
risk of hypersensitivity, on the other hand it may deny optimal treatment to individuals who could tolerate the
drug and oblige the clinician to prescribe less efficient and/or more expensive alternative therapies.
In view of all these premises, only few HLA hypersensitivity drug associations reported so far will be translated
into clinical routine as pretreatment screening tests. Nevertheless, beside the prospective use of genotyping to
predict and prevent ADRs, pharmacogenetic tests can also be exploited for clinical diagnosis. In this context,
the genetic test is performed at the time of the ADR in exposed patients rather than prior to drug prescription.
Flucloxacillin-induced cholestatic hepatitis is strongly associated with the presence of HLA-B*57:01 allele (OR
108), but due to its extremely low prevalence (8.5 cases/100,000 treated patients), it has been estimated that
13,500 subjects would need to be screened to prevent one case of HDR. As a consequence, pre-administration
testing would not be cost-effectively applicable in clinical routine [40,93–95]. However, the very-high NPV (almost
100%) suggests a role of HLA-B*57:01 genotyping as differential diagnosis tools in patients exposed to flucloxacillin
presenting an acute liver disease in order to exclude drug-related hepatitis. The usage of genetic test for diagnostic
purpose would be potentially applicable for other drug-induced liver injury in which NPV of nearly 100% would
permit to effectively rule out the drug as putative cause for liver toxicity. Examples include, but are not limited
to: amoxicillin-clavulanic acid (HLA-DRB1*15:01) and lapatinib (DRB1*07:01 and DQA1*02:01) [88]. Because
serious HDRs are very rare, they are seldom detected during preclinical testing (animal models) or clinical trials,
and, in the majority of cases, they are identified during postmarketing when a large number of patients have been
treated. This often results in the drug’s withdrawal from the market. As a consequence, HDRs represent a major
cost burden for pharmaceutical industry contributing to the elevated costs of drug development. A systematic
DNA banking during drug development could allow, if an HDR occurs, to retrospectively identify a susceptibility
genomic biomarker. The availability of predictive marker could avoid market withdrawal by individualizing the use
of the drug to genetically tolerant individuals [96].
The notion that some HDRs are related to specific HLA alleles and can be prevented by prospective phar-
macogenomics testing, has made HDRs (at least some of them) preventable thus breaking the dogma of their
unpredictability. Currently, a huge number of HLA-related HDRs has been described, but there are still many
hurdles to overcome before these associations could be translated into the clinical practice, and only few of them
have been successfully implemented so far. Thus, it is clear that there is a great potential for pharmacogenomics of
HLA to improve the tolerability profile of drugs, but, at the same time, there is also the need for further research.
In this scenery, efforts should be made in order to improve both multidisciplinary basic and clinical research, going
from bench to bedside and then back, from bedside back to bench. Basic research could add important insights
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to the immunopathogenic mechanisms of these syndromes, allow the development of diagnostic tests and improve
drug design by predicting immunogenicity of a given compound at the preclinical stage of its development. On
the other hand, the qualitative and quantitative improvement of the clinical research protocols (e.g., prospective
clinical trials, collaborative consortia and international registries) may help to define the real clinical validity and
cost–effectiveness of a given association, providing more robust bases for its translation into the routine clinical
practice.
Before concluding this review focused on immune-mediated ADRs, mention ought to be made of adverse
events related to checkpoint inhibitor agents. Immune checkpoint inhibitors are drugs, typically monoclonal
antibodies, which block specific molecules (immune checkpoints) that negatively regulate the immune response.
Physiologically, these inhibitory pathways serve to ‘switch off ’ the immune response when it is no longer required
in order to prevent tissue injury and autoimmunity. Therefore, immune checkpoint blockade ‘by inhibiting the
inhibition of the immune response’ unleash the immune system against cancer cells [97].
Overall, immune checkpoint inhibitors are well-tolerated drugs, particularly when compared with standard
cytotoxic agents, nevertheless they can induce a broad spectrum of immune-related toxicities [98]. Immune-related
ADRs triggered by immune checkpoint inhibitors can affect virtually every organ system (e.g., skin, GI tract,
endocrine system, liver, etc.) and can be extremely debilitating and potentially life threatening [98]. Although the
precise pathophysiologic mechanisms responsible for these ADRs are not completely understood, they are commonly
considered to be dependent on the overactivation of the immune system resulting in autoimmune reactions [98–
100]. Accordingly, immune-related ADRs induced by checkpoint inhibitors are ascribable to the pharmacologic
(immunostimulatory) properties of the drug, and are therefore classifiable as type A ADRs sensu stricto [100].
To the best of our knowledge, no associations between ADRs triggered by checkpoint inhibitors and specific HLA
alleles (or haplotypes) have been reported to date in the literature, nevertheless this topic represents an extremely
interesting field which deserves to be explored in the future.
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Executive summary
 Pharmacogenomics studies the genetic bases of drug efficacy and toxicity in order to optimize drug prescription
practice thus contributing to the so-called tailored, or personalized medicine.
 A growing number of studies have demonstrated strong associations between specific HLA alleles and
susceptibility to develop delayed drug hypersensitivity reactions.
 Different models have been proposed to explain how drugs, generally too small to be immunogenic, can activate
T cells. These, nonmutually exclusive theories are: the ‘hapten/prohapten model’, the ‘pharmacologic interaction
(p-i) with immune receptors concept’ and the ‘altered peptide repertoire hypothesis’.
 Despite the huge number of HLA-related hypersensitivity drug reactions (HDRs) described so far, only very few
pharmacogenomics screening tests have been successfully translated into routine clinical practice.
 HLA–drug–HDR associations that have more robust pharmacogenetic data include abacavir hypersensitivity
syndrome (HLA-B*57:01) and severe cutaneous reactions induced by carbamazepine and allopurinol
(HLA-B*15:02 and HLAB*58:01, respectively).
 HLA pharmacogenomics has demonstrated that ‘unpredictable’ HDRs, at least for some compounds, could be
prevented by genetic testing.
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